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The impact generated by publicly and
charity-funded research in the United
Kingdom: a systematic literature review
Daniela Gomes and Charitini Stavropoulou*
Abstract
Objective: To identify, synthesise and critically assess the empirical evidence of the impact generated by publicly
and charity-funded health research in the United Kingdom.
Methods: We conducted a systematic literature review of the empirical evidence published in English in peer-
reviewed journals between 2006 and 2017. Studies meeting the inclusion criteria were selected and their findings
were analysed using the Payback Framework and categorised into five main dimensions, namely knowledge,
benefits to future research and research use, benefits from informing policy and product development, health and
health sector benefits, and broader economic benefits. We assessed the studies for risk of selection, reporting and
funding bias.
Results: Thirteen studies met the inclusion criteria. The majority of the studies (10 out of 13) assessed impact at
multiple domains including the main five key themes of the Payback Framework. All of them showed a positive
impact of funded research on outcomes. Of those studies, one (8%), six (46%) and six (46%) presented a low,
moderate and high risk of bias, respectively.
Conclusions: Empirical evidence on the impact of publicly and charity-funded research is still limited and subject
to funding and selection bias. More work is needed to establish the causal effects of funded research on academic
outcomes, policy, practice and the broader economy.
Keywords: Research impact, Public and charity funding, Evidence
Background
Every year, public and charity funding bodies in the
United Kingdom invest significantly in health research.
In 2014 alone, the United Kingdom Clinical Research
Collaboration reported an expenditure of approximately
£3.01 billion in health research funded by public and
charity sources [1], with the Medical Research Council,
the National Institute of Health Research (NIHR) and
the Wellcome Trust being ranked among the top public
and philanthropic funders of health research worldwide
[2]. Thanks to this investment, a number of achieve-
ments have been possible and the United Kingdom “has
developed some of the strongest and most productive clin-
ical medicine research bases in the world” [3].
Given the magnitude of the investment in health re-
search, there has been a growing interest in exploring
the impact it generates. However, defining and measur-
ing research impact is not straightforward; it is a com-
plex exercise and the growing international interest on
this subject has led to the development of multiple ap-
praisal frameworks. A recent literature review identified
24 different methodological research impact frameworks
that have been used in various countries and settings [4],
with the Payback Framework being the most commonly
used [5] both in the United Kingdom and internationally
[4, 6, 7]. The Payback Framework was developed by
Buxton and Hanney [8] and measures impact in five di-
mensions, namely knowledge, benefits to future research
and research use, benefits from informing policy and
product development, health and health sector benefits,
and broader economic benefits.
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Using the Payback Framework, this study’s aim is to
review, synthesise and critically assess the empirical evi-
dence of the impact generated by publicly and
charity-funded health research in the United Kingdom.
We do so acknowledging that there is inherent uncer-
tainty regarding the outcomes of health research, in par-
ticular blue-sky and preclinical investigation [9]. We also
accept that different types of research are expected to
have different impact, with implications in the final as-
sessment of research.
Methods
Data sources and searches
To address the study’s aim we conducted a systematic
literature review. The Electronic Databases considered
in this review were DoPHER (Database of Promoting
Health Effectiveness Reviews), EBSCOhost CINAHL
(Cumulative Index to Nursing and Allied Health Litera-
ture), EBSCOhost MEDLINE, OVID Embase, CEN-
TRAL (Cochrane Central Register of Reviews of Effects),
CDSR (Cochrane Database of Systematic Reviews),
DARE (Database of Abstracts of Reviews of Effects), and
NHS EED (NHS Economic Evaluation Database).
Searches were conducted using a combination of key-
words and index terms (for example, MeSH terms) com-
bined with Boolean operators, as part of an extensive
search. These were adapted to the other relevant elec-
tronic databases using the synonyms used by each data-
base. The search terms included combinations of
different relevant terms, such as ‘budget’, ‘funding’, ‘in-
vestment’, ‘grant’, ‘research support’, ‘clinical research’,
‘health research’, ‘medical research’, and ‘impact’, ‘value’, or
‘research outcome’. A full list of search terms and an ex-
ample of the search strategy of the three main databases
(OVID Embase, EBSCOhost CINAHL and EBSCOhost
MEDLINE) is available in Additional file 1 to enable rep-
lication. One author (DG) performed the search of the
electronic databases.
In addition, citation tracking of relevant literature and
reference lists of the identified studies and reports were
searched for further studies by both authors. Hand
searches were also conducted in the key journals Value
in Health, The Journal of Health Economics and BMC
Health Services Research.
Study selection
We included empirical studies that (1) explicitly ana-
lysed the impact generated by research funding provided
by public and charity bodies in the United Kingdom, (2)
analysed the impact generated in the United Kingdom
or other countries, (3) were published between 2006 (the
year the NIHR was lunched) and 2017, (4) were peer
reviewed and (5) were written in English. We excluded
speculative studies, opinion papers or editorials that
discussed the potential impact generated by funded re-
search in the United Kingdom and studies that did not
focus on health-related research.
The selection of the relevant studies followed the steps
identified by the PRISMA guidelines for systematic re-
views and meta-analyses [10]. First, we screened all re-
cords on the basis of title and abstract. When it was not
possible to determine whether a study met the inclu-
sion/exclusion criteria based on title and abstract review,
we included the study for full text review. Both authors
screened all records, assessed the list of studies included
for full text review and agreed on the final list.
Data extraction and data synthesis
Following the identification of the studies, data extrac-
tion and quality assessment was conducted using a stan-
dardised data extraction form. Extracted data included
aims, programme assessed, methods, outcomes assessed
and main findings. Given the diversity of the methodo-
logical approaches used in the identified studies, a quan-
titative analysis of the results was not possible. Overall,
the results were synthesised into the five key domains of
the Payback Framework, using the adaptation discussed
in Donovan and Hanney [11], in which payback from re-
search includes the following five main dimensions and
definitions:
1. Knowledge, including articles published in peer-
reviewed journals, conference presentations, books,
book chapters and research reports.
2. Benefits to future research and research use, such
as better targeting of future research, development
of research skills, personnel and overall research
capacity, a critical capacity to appropriately absorb
and utilise existing research, including that from
overseas, staff development, and educational
benefits.
3. Benefits from informing policy and product
development, improved information bases for
political and executive decisions, other political
benefits from undertaking research, and
development of pharmaceutical products and
therapeutic techniques.
4. Health and health sector benefits, including not
only health improvements but also cost reduction
in delivery of existing services, qualitative
improvements in the process of delivery, and
improved equity in service delivery.
5. Broader economic benefits, wider economic
benefits from commercial exploitation of
innovations arising from research and development
(R&D), and economic benefits from a healthy
workforce and reduction in working days lost.
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Risk of bias assessment
Given the heterogeneity of the studies included, we de-
cided to develop a simple tool to assess the risk of bias.
The tool focused on three main types of risk of bias,
namely funding, selection and reporting bias. Funding
bias refers to the potential tendency for the study to sup-
port the interests of the sponsor. Selection bias occurs
when selected samples (including individuals, groups or
data) are not representative of the population being
reviewed. Reporting bias refers to the reported data
favouring certain outcomes or key aspects of the study
not being clearly described.
Each study was assessed and was given a score for
each of the three types of bias using the risk of bias tool
described in Table 1. An overall score was then calcu-
lated in the following way – studies with no high-risk
score in any of the three domains were classified as ‘low
risk of bias’, those with two high-risk scores were
classified as ‘moderate risk of bias’ and those with three
high-risk scores were classified as ‘high risk of bias’.
Results
Study inclusion
The process of study selection is summarised in Fig. 1
and follows the PRISMA guidelines. From the main
database searches (CINAHL n = 94, EMBASE n = 204
and MEDLINE n = 112) a total of 410 studies were iden-
tified. An additional 31 studies were identified by other
searches, including CENTRAL, CDSR, DARE, DoPHER,
Google Scholar, National Institute for Health and Clin-
ical Excellence (NICE) and NHS EED, as well as key
journals, citation tracking and the main funding web-
sites. After removing 62 duplicates, we proceeded with
the review of the title and abstract of the remaining 379
studies. At this stage, 331 studies were excluded and the
remaining 48 were retrieved as full text for further re-
view, which are listed in Additional file 2.
Following full text review, 34 studies were excluded;
14 did not have a primary focus on the impact of public
and charity funded research, 12 considered funding out-
side the United Kingdom, five did not provide empirical
evidence, two were not peer-reviewed and one was pub-
lished before 2006. One study was excluded to avoid du-
plication since it was a brief journal article [12] of an
earlier report [13]. This resulted in 13 studies being in-
cluded for analysis.
Study characteristics
The data extraction table can be found in Additional
file 3. The funding body mostly assessed in the studies
included was the NIHR. Three studies focused on the
NIHR’s Health Technology Assessment (HTA)
Programme, one on its Service Delivery and Organisa-
tion (SDO) R&D Programme, one study looked at the
NIHR’s Biomedical Research Centre at Oxford, one ex-
plored the impact of two NIHR-funded research net-
works, one analysed the NIHR-funded Cochrane Review
Groups (CRGs) and, finally, one looked at the 10 years
of the NIHR. Four studies looked at specialised charities
including the United Kingdom Occupational Therapy
Research Foundation, Asthma UK, the National Cancer
Research Institute and leading funders of cancer
research in the UK. Finally, one study took a wider
approach looking at the general economic effect of
government and charity research expenditure on
pharmaceutical R&D.
Out of the 13 studies, seven (54%) used mixed
methods, three (23%) used quantitative and three (23%)
used qualitative methods. A number of different designs
were used, including questionnaire surveys (n = 4),
qualitative interviews (n = 5), case studies (n = 3), docu-
ment review (n = 3), bibliometric analysis (n = 3) and
Table 1 Risk of bias assessment tool
Risk of
bias
Rationale Relevant points and relative
scoring
(1 = low risk; 2 =medium risk;
3 = high risk)a
Funding
bias
Potential tendency for the
study to support the
interests of the sponsor
What was the role of the
evaluated funding body in
the financing of the study?
1. The study or its author(s)
did not receive funding from
the body they evaluate
2. The study or its author(s)
were partly funded by the
body they evaluate
3. The study or author(s) was






groups or data) are not
representative of the
population studied
Is the selected sample likely







The reported outcomes are
inaccurate or inappropriate
Are all aspects of the study
(including aims, methods
and results) clearly described
and reported? Is there a
balance between reported
data/opinions and critical
analysis or are these
consistently more favourable
of the outcome/funding in
analysis?
1. All aspects of the study
clearly described with
supporting evidence
2. Some aspects/evidence of
the study are not clear
3. Several aspects/evidence
of the study are missing with
difficult interpretation of the
findings
aOverall rating for risk of bias: 1 (strong; no high-risk score); 2 (moderate: 1–2
high-risk scores); 3 (weak; 3 high-risk scores)
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quantitative analysis using econometric techniques (n =
3). The design of the studies was such that none of the
studies could establish causality between research fund-
ing and various outcomes. Only one study explored the
hypothesis that publicly and charity-funded research led
to increased pharmaceutical R&D, but using appropriate
econometric tests, it showed that there may be a dual
causal relationship between the two. The authors there-
fore conclude that their results should be interpreted as
a positive association between public expenditure and
private R&D, and cannot claim causality [14].
Risk of bias
All reviewed studies had received funding, partly or
exclusively, by the organisation they were assessing.
High risk of selection bias was present in seven out
of the 13 studies (54%), as they chose to analyse
funded projects that were more likely to have shown
positive impact. Finally, reporting bias was high in
more than half of the studies (8/13; 62%), either be-
cause important information regarding the methods,
funding sources or results was missing, or because
the overall claims of the studies highlighted predom-
inantly data showing positive impact of research.
Overall, from the included studies only one presented
a low risk of bias (8%). All of the remaining included
studies presented a moderate (6/13; 46%) to high risk
of bias (6/13; 46%), accounting for an estimated 92%
of the included studies. The results are presented in
Table 2.
Data analysis
The results of the final 13 studies were synthesised in
accordance to the Payback Framework domains.
Knowledge
Eight of the included studies report research impact as a
form of knowledge generation [13, 15–21]. Two of these
studies focused on the NIHR’s HTA Programme. In
2007, Hanney et al. [13] assessed the impact of the first
10 years of the programme and showed that the mean
number of publications per project was 2.93 (1.98 ex-
cluding the monographs). A more recent study by Guth-
rie et al. [16] reported that an estimated 96% of the
NIHR-funded HTA Programme studies are published in
the journal Health Technology Assessment; the authors
claimed that work funded by the HTA Programme is
cited more than twice as frequently as would be ex-
pected on average.
Two more studies looked at knowledge generated by
programmes funded by the Department of Health in the
United Kingdom. Peckham et al. [19] assessed the im-
pact of the first 5 years of the SDO Programme (2001–
2006) and showed that, of the 23 research projects, a
total of 39 papers had been published in peer-reviewed
journals by early 2006, equivalent to 1.7 articles per pro-
ject. In addition, there were 95 national and inter-
national conference presentations. Each of the 23
research projects produced an average of 6.7 citations.
Another study by Bunn et al. [15] assessed the reviews
published by 20 NIHR-funded CRGs, showing that 1502
Fig. 1 Flow diagram of study selection following the PRISMA guidelines
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out of 3187 (47%) new and updated reviews published
on the Cochrane Database between 2007 and 2011 were
published by the 20 CRGs. In addition, in a sample of 60
reviews (out of 1502), 27 presented 100 or more cita-
tions and five out of 60 were cited over 400 times in
Google Scholar.
Two studies looked at knowledge generated by two
charity funders. Hanney et al. [20] described the various
impacts identified from a range of Asthma UK research
by conducting a survey among investigators of funded
projects. Of the 90 projects that were returned, they
showed an average of four peer-reviewed journal articles
per project. Four respondents did not record producing
any articles. As the authors pointed out, the results may
be biased as it is possible that those projects for which
surveys were not returned had a much lower number of
publications. Another study by Sainty [17] looked at the
United Kingdom Occupational Therapy Research Foun-
dation (UKOTRF) by sending a questionnaire form to 11
grant holders. They concluded that knowledge gener-
ation was the main self-reported outcome by previous
grant holders; this outcome was measurable through re-
ported scientific publications in peer-reviewed journals
(publications n = 6; submissions n = 14), publication of
books/book chapters (n = 2), Cochrane review citations
(co-authorship of a Cochrane review n = 1) and confer-
ence presentations (presentation at UKOTRF n = 1; sub-
mission to annual conference and other national and
international conferences n = 39). They note that it is a
requirement of the UKOTRF grant holders to submit an
article to the British Journal of Occupational Therapy
and an abstract to the organisation’s annual conference.
Sullivan et al. [18] compared the period before and
after the launch of the National Cancer Research Insti-
tute in the United Kingdom in 2001, an initiative that
brought together charity and public funders in the area
of cancer research. They showed that UK cancer centres
published just over one-eighth of all UK outputs (papers
per year) in 1995 but almost a quarter by 2004.
Finally, Morgan Jones et al. [21] highlighted the impact
of the NIHR in managing and sharing knowledge re-
sources via the Journals Library and BioResource.
Benefits to future research/research use
Better targeting of future research was reported as an
outcome of funded research in four of the reviewed
studies [13, 15, 16, 21]. In particular, the study by Mor-
gan Jones et al. [21] that reviewed a number of NIHR
cases gave a lot of emphasis on better targeting of future
research as a result of NIHR-funded research. The re-
port presented 10 cases showing collaboration with char-
ities and the third sector, including, for example, the
collaboration of NIHR with the Stroke Association in re-
search that has resulted in earlier and more efficient
diagnosis for stroke survivors with cognitive impairment.
In their analysis of the NIHR-funded CRGs, Bunn et al.
[15] showed that 13 out of 60 Cochrane reviews con-
ducted by the CRGs were cited in protocols or primary
research. In addition, respondents of the survey provided
40 examples where they felt their reviews influenced pri-
mary research. However, Bunn et al. [15] reported that
most of these examples of impact relate to work con-
ducted by the Cochrane reviewers themselves. There-
fore, there is limited evidence of a broader impact.
Two studies analysing NIHR’s HTA showed the pro-
gramme’s contribution to future research. Hanney et al.
[13] showed that 61 (46%) HTA projects went on to re-
ceive further funding, yet it is not clear whether this
funding was from the HTA or other bodies. A few years
later, Guthrie et al. [16] showed that HTA funding
Table 2 Risk of bias assessment
Author/Year Funding bias Selection bias Reporting bias Total score
Bunn et al., 2014 [15] 3 2 2 2
Glover et al., 2014 [24] 2 3 2 2
Guthrie et al., 2015 [16] 3 2 2 2
Guthrie et al., 2016 [23] 3 3 3 3
Hanney et al., 2007 [13] 3 1 2 2
Hanney et al., 2013 [20] 3 3 3 3
Lichten et al., 2017 [25] 3 3 3 3
McCrae et al., 2012 [22] 3 2 3 2
Morgan Jones et al., 2016 [21] 3 3 3 3
Peckham et al., 2008 [19] 3 3 3 3
Sainty, 2013 [17] 3 3 3 3
Sullivan et al., 2011 [18] 2 1 3 2
Sussex et al., 2016 [14] 2 2 1 1
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contributed to the development of new research
methods, by stimulating their research field more widely
or by introducing new research priorities as a result of
its findings. This evidence was provided in approxi-
mately 58% of the case studies, with examples of the
studies provided as supporting evidence. Half of the
studies were extended; however, there was little evidence
that there was broader impact beyond those already
holding HTA grants.
Six of the reviewed studies provided a series of exam-
ples through which funded research has contributed to
the development of research skills, personnel and overall
research capacity as well as enabling staff development
and educational benefits [13, 16, 18, 19, 21, 22]. Guthrie
et al. [16] addressed the HTA Programme’s contribu-
tions to career development of researchers and overall
research capacity through interviews of 20 stakeholders.
Six out of the 20 interviewees reported contributions to
career development and overall research capacity. The
authors indicate that capacity-building is hard to estab-
lish, as most of the researchers receiving the grant were
already established. In an earlier study, Hanney et al.
[13] showed that 28 projects out of 133 completed ques-
tionnaires reported that qualifications had been gained
or were expected to be gained from involvement in HTA
projects. In addition, eight out of the 16 case studies
they analysed reported that researchers involved in the
funded projects progressed in their career through pro-
motions, though the authors acknowledge that it is hard
to tell this was the outcome of the funded project.
The report by Morgan Jones et al. [21] gave particular
emphasis on the development of overall research capacity
by developing or facilitating knowledge improvement and
research teams in areas of research otherwise difficult to ad-
dress. This was reported in three studies, namely (1) the
Radiotherapy Trial Quality Assurance Team, supporting
medical staff implementing research knowledge to practice;
(2) the Hyper-acute Stroke Research Centres, enabling
patient-informed decision and participation in treatment
therapy trials to improve the delivery of better emergency
care; and (3) the Enabling Research in Care Homes, involv-
ing the development of a research network at care homes.
According to Morgan Jones et al. [21] the NIHR also recog-
nises the relevance of retaining researchers following com-
pletion of funded research. The report referred to the
Doctoral Research and Clinical Research Fellowships, the
Leadership Programme and the Mentorship for Health Re-
search Scheme. Furthermore, the report provided evidence
that NIHR funding has contributed to the critical capacity
to absorb and appropriately utilise existing research, includ-
ing international research in five studies. The evidence was
reflected in the centralisation of specialist cleft services and
support in national and international trials; standardisation
of children eczema treatment based on international
guidelines; improvement of rehabilitation programme to
stroke survivors; introduction of a personalised care ap-
proach to elderly patients with dementia; and collaboration
in testing of artificial knee joints produced by foreign
manufacturers.
McCrae et al. [22] examined the impact of two
NIHR-funded research networks on a multi-centre ran-
domised controlled trial of antidepressants in people
with depression superimposed on dementia. The two
networks are the Mental Health Research Network and
the Dementia and Neurodegenerative Diseases Research
Network. They showed that the Mental Health Research
Network helped in gaining local ethics committee and
NHS trust approvals, which can be a time-consuming
process. Clinical study officers boosted a recruitment
campaign and contributed to the monitoring and assess-
ment of participants. The study mentioned a number of
limitations of the networks, including potential problems
of duplication or unclear roles and responsibilities, a de-
gree of unrealistic expectation from principal investiga-
tors and additional bureaucratic burden.
The study by Sullivan et al. [18] showed that, following
the establishment of the National Cancer Research Insti-
tute, there has been an increase in United Kingdom can-
cer centre collaborations with European (5–28% of all
their outputs) and United States (6–21%) investigators.
Peckham et al. [19], evaluating the first years of the
SDO, argued that the projects demonstrate contribu-
tions to building the capacity of the workforce, as there
are many examples from the bibliographic analysis and
the case studies where the knowledge is used in teaching
in universities. There was also some evidence that the
research is stimulating user involvement in research.
In charity funding, Hanney et al. [20] showed that at
least 62 higher degrees have been obtained or were ex-
pected, at least partly, as a result of Asthma UK’s project
funding. In addition, 64% of the funded projects partici-
pating in the survey reported some career development,
including promotion for principal investigators, further
fellowships from major funders and recognition in the
asthma field as a result of the Asthma UK project fund-
ing. Sainty [17] reported that funded research by the
UKOTRF has not only contributed to promotion of the
researcher’s profile and career progression but also to
overall research capacity by enabling collaborative work-
ing with clinical organisations, universities and charit-
able partners. In addition, funding led to employer and
other partner/host organisations contributions and
attracted follow-on funding from external sources.
Benefits from informing policy and product development
Eight of the included studies assess the benefits of
informing policy as a form of research impact [12, 13,
15–17, 19, 20, 23]. The main methods used to measure
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the impact were self-reported evidence from recipients
of grants, citations in policy documents and case studies.
Surveys were used in four studies [13, 16, 17, 20].
Three out of the 11 respondents in the study by Sainty
[17] reported that their findings were particularly rele-
vant to inform discussions at a national policy event (n
= 1) and national and regional dissemination forums (n
= 2). Using a questionnaire survey, Hanney et al. [13]
showed that 73% of the respondents claimed their study
had an impact on policy to date, particularly for NICE
projects. Hanney et al. [20], looking at Asthma UK,
showed that 13% of the respondents claimed to have
made an impact on policy, and 17% expected to do so in
the future. Using Researchfish data, Guthrie et al. [16]
provided evidence that 15% of the portfolio of studies
analysed had an impact on policy, including participa-
tion in advisory committees and citations in clinical re-
views, policy documents and guidelines.
Citations in policy documents were used as evidence
of policy influence in two studies [15, 18]. Bunn et al.
[15] claimed that Cochrane reviews have contributed to
informing policy, with an estimated 722 citations identi-
fied in 248 guidelines and 481 reviews cited at least
once. They included several sets of developed guidance
at a local (n = 10), national (n = 175) and international
level (n = 62). Sullivan et al. [18] showed that, after the
establishment of the National Cancer Research Institute
in the United Kingdom, there has been an increase in
the number of citations on clinical guidelines and the
press (BBC).
Interestingly, the evaluation of the SDO by Peckham
et al. [19] reveals differences in evidence of policy influ-
ence depending on the method used. The literature re-
view they conducted did not identify any citations in the
documents related to policy, but evidence from inter-
viewees indicates other informal mechanisms in which
the knowledge was transmitted to policy such as meet-
ings with the Department of Health. This demonstrates
that knowledge can be effectively transferred in different
ways but these may be difficult to trace when building
an understanding of knowledge flow and research out-
put. It has been difficult to confirm the use of
SDO-funded research by practitioners through case
studies. The data on outputs show that there is potential
for a wide range of practitioners to access the research.
Certain studies referred to specific policies or policy
organisations mainly due to the nature and scope of the
funding body assessed. Guthrie et al. [16] showed that
funding by the HTA Programme enhanced the existent
collaboration between the programme, NICE and the
National Screening Committee, who represent powerful
identities in the process of disseminating research find-
ings through policy and guidelines. According to Guthrie
et al. [16], 15% of the overall portfolio of HTA-funded
studies reported having some impact on policy. HTA
Programme research has the potential to constitute and
improve the information base for policy development
and redesign at both national and international levels;
however, it is not primarily involved in the direct process
of policy development. Guthrie et al. [23] presented
similar findings in a later study. Earlier assessments of
the HTA showed similar impacts. Hanney et al. [13]
showed that the HTA’s Technology Assessment Reports
for NICE had the clearest impact on policy in the form
of NICE guidance. Other bodies where the projects had
impact included the National Screening Committee, the
National Service Frameworks, professional bodies or the
Department of Health. The case studies they presented
provided considerable detail about the exact names of
the policy documents informed by specific HTA pro-
jects, and the precise issues in the documents that were
influenced by the specific research.
Finally, evidence that publicly funded research leads to
development of pharmaceutical products and thera-
peutic techniques was found in one of the reviewed
studies only. Morgan Jones et al. [21] provide evidence
on the development of therapeutic techniques which are
“safer, less invasive and more focused on patients’ quality
of life” by NIHR-funded research. They also provide evi-
dence from seven funded studies, which led to more effi-
cient and cost-effective treatments.
Health sector benefits
Regarding improved health outcomes, the majority of
the studies provided self-reported evidence. In the study
by Sainty [17], three out of 8 respondents reported that
their research findings were being applied to local prac-
tice, yet no specific details are given. Respondents to the
study by Bunn et al. [15], assessing the impact of
NIHR-funded Cochrane reviews, reported that 19 out of
60 of the Cochrane reviews assessed indicated potential
to lead to health and health sector benefits. However,
the majority were unable to provide evidence if these
have led to changes in practice, improved health, im-
proved equity and quality in service deliver, or cost re-
duction in delivery of existing services. According to
Hanney et al. [20], only a small minority (10%) of the re-
spondents sponsored by Asthma UK claim to have
already made an impact in any of the various forms this
could take, with 6% believing they had made an impact
specifically to health. In addition to the survey, three of
the 14 case studies analysed by Hanney et al. [20] “de-
scribed health gains from Asthma’s UK-funded contribu-
tions to research on leukotriene receptor antagonists and
on immunotherapy for allergic rhinitis, and the potential
health gains from research on peptide immunotherapy”.
Case studies were also used by Peckham et al. [19] to
demonstrate a range of ways in which NHS managers
Gomes and Stavropoulou Health Research Policy and Systems           (2019) 17:22 Page 7 of 11
and policy-makers have used SDO-funded research to
develop service delivery.
Morgan Jones et al. [21] provide more specific evi-
dence on research findings that have contributed to im-
proved health and improved equity in service delivery
nationally and internationally. The evidence in the three
studies provided include a reduction of people dying
from traumatic injury bleed by administration of tranex-
amic acid, reduction of post-operative complications by
using WHO’s Surgical Safety Checklist and a reduction
of the number of people at risk of death by withdrawing
co-proxamol.
Two studies, whose primary focus was to estimate the
economic benefits of funded research, provided evidence
of health gains. Glover et al. [24], analysing the eco-
nomic returns from United Kingdom publicly and
charity-funded cancer-related research, estimated that
there were 5.9 million QALYs gained from the priori-
tised interventions from 1991 to 2010. Similarly, Guthrie
et al. [23] estimate economic benefits as monetary gains
over QALYs. However, a total number of QALYs gained
is not provided.
There was one study that showed mixed findings.
Lichten et al. [25] evaluated the impact of the Oxford
Biomedical Research Centre, which is funded by the
NIHR. They interviewed both research leaders and se-
nior clinicians, and founded interesting differences be-
tween the two groups. The research leaders identified a
wide range of beneficial impacts that they expected
might be felt at local hospitals as a result of their re-
search activity. The senior clinicians responsible for pa-
tient care at those hospitals presented a more mixed
picture, identifying many positive impacts, but also a
smaller number of negative impacts, from research activ-
ity, such as duplication of roles.
Four studies reported qualitative improvements in the
process of delivery and cost reduction in delivery of
existing services. The study by Sainty [17] suggested that
the funded studies assessed have contributed to quality
improvements and cost reduction in delivery of existing
services. One respondent to the survey reported that
work was already being carried out to translate the re-
search findings into commissioning of services by the
local trust, which is likely to contribute to more
cost-effective service delivery. Another respondent
claimed that the implementation of the research findings
to clinical practice had the potential to lead to safer and
more cost-effective services.
Morgan Jones et al. [21] also drew attention to the
contributions of NIHR-funded research to quality im-
provements in the process of delivery and cost reduction
in delivery of services in a diverse range of areas, includ-
ing improvement to screening methods in newborn ba-
bies, improvement to stroke prevention and reduction of
associated costs, implementation of new therapies by re-
duced cost of antipsychotic medication in dementia pa-
tients by implementation of cognitive stimulation
therapy, improved health promotion, improved commis-
sioning of services, and prevention of spreading of
life-threatening communicable diseases.
According to the interviews they conducted, Guthrie
et al. [16] showed that the HTA Programme is recog-
nised as high-quality funded research and, as a result,
more likely to be translated into clinical guidelines, ap-
plied to practice and ultimately lead to improved health.
Case studies were also analysed and seven out of 12
studies provided evidence that the HTA Programme has
contributed to health and health sector benefits, which
included improved health, improved equity in service
delivery and more cost-effective service delivery. Despite
this, is it not possible to infer that health benefits re-
sulted directly as a unique result of the HTA
Programme. Some of the studies analysed failed to pro-
vide significant evidence on this matter, with the possi-
bility that the final outcome has resulted from a
combination of factors, including multiple studies’ find-
ings applied to practice. Additionally, two of the studies
concluded that their findings matched the current guid-
ance already in place, limiting the interpretation of the
value generated by their research.
Similar challenges were seen in the study by Hanney
et al. [13]. Eight out of the 16 studies reported it was im-
possible, unlikely or unrealistic to show any health gains,
or that the evidence was too limited to show any health
improvements. Another six talked about potential health
gains and two discussed health improvements.
Broader economic benefits
Six of the included studies assess the economic impact
as a result of research findings. Glover et al. [24]
assessed the monetary returns from publicly and
charity-funded cancer-related research. They showed
that, in 2011/2012 prices, the net monetary benefit of
the 5.9 million QALYs gained from the prioritised inter-
ventions from 1991 to 2010 was £124 billion. Their esti-
mated internal rate of return incorporated an estimated
elapsed time of 15 years. The paper related 17% of the
annual net monetary benefit estimated to be attributable
to United Kingdom research (for each of the 20 years be-
tween 1991 and 2010) to 20 years of research investment
15 years earlier (that is, for 1976 to 1995); this produced
a best-estimate internal rate of return of 10%.
Sussex et al. [14] inferred that there are wider eco-
nomic benefits from public and charitable R&D expend-
iture, as well as a correlation between this and private
R&D expenditure; every £1 of public research expend-
iture is associated with an additional £0.83–£1.07 of pri-
vate sector R&D spend. They show that 44% of that
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supplementary private sector expenditure occurs within
1 year, with the remainder accumulating over decades.
This spill-over effect implies a real annual rate of return
(in terms of economic impact) to public biomedical and
health research in the United Kingdom of 15–18% and,
when combined with previous estimates of the health
gain that results from public medical research in cancer
and cardiovascular diseases, the total rate of return
would be approximately 24–28%.
Morgan Jones et al. [21] provided evidence from seven
studies on the wider economic benefits from commercial
exploitation of innovations arising from R&D, through
NIHR-funded research at the levels of attraction of pri-
vate funding for public–private partnerships to further
potential, investment in innovative research that leads to
development of pioneering advanced prototypes, invest-
ment in quantifying impacts of new therapies that can
improve patients’ lives whilst reducing current expend-
iture, and attracting foreign manufactures investment in
the United Kingdom for trial of innovative drugs, devices
and diagnostics.
Guthrie et al. [16], in their overall assessment of the
HTA Programme, claimed that there is little overlap be-
tween HTA and industry and showed that half of the
studies showed impact on industry. The team then went
ahead to conduct a full economic analysis of the impact
of the HTA Programme [23], finding significant eco-
nomic impact and arguing that, if 12% of the potential
net benefit of implementing the findings of this sample
of 10 studies for 1 year was realised, it would cover the
cost of the HTA Programme from 1993 to 2012.
Yet, the evidence was not always easy to show. Hanney
et al. [20] provided limited evidence that Asthma
UK-funded research brought benefits to the broader
economy, though they do mention the development of
two spin-out companies in the United Kingdom result-
ing from this. The study by Sainty [17] stated that only
one out of eight respondents addressed economic im-
pact by claiming that the submission of an economic
paper to the British Journal of Occupational Therapy
had the potential to generate economic benefits. Yet,
there is no clear evidence on how this economic benefit
would be generated and to whom or which services.
Conclusions
Funding is absolutely vital for research and funders and
researchers are under pressure to show that money is
well spent. Our study shows that the number of
peer-reviewed papers that explore the impact of publicly
and charity-funded research in the United Kingdom is
limited, but it is growing. The majority of the studies
reviewed (10/13) assessed impact at multiple domains of
the Payback Framework. All studies argue that publicly
and charity-funded research has a positive impact on
most domains. Impact on knowledge was the easier di-
mension to quantify and measure, using bibliometric
techniques such as number of publications and citations
generated per project. In other domains, including im-
pact on policy and practice, it is harder to demonstrate
impact and evidence is mainly self-reported. However, it
is expected that the Research Excellence Framework, a
performance-based research funding system of higher
education institutions in the United Kingdom [26], is
likely to improve the way impact outside academia is
assessed and measured and force researchers to devise
better tools to achieve this. Yet, care should be given to
avoid the selection and reporting bias that current Re-
search Excellence Framework cases are likely to present
when reporting impact.
The majority of the studies presented moderate to
high risk of bias. All studies had received funding from
the body they were assessing, raising concerns about the
potential tendency of these studies, whether real or per-
ceived, to support the interest of the funder. This is a
concern raised by the authors of some of these studies
[26], calling for more independent funding streams for
research evaluation. In addition to funding bias and per-
haps not unrelated to it, eight out of 13 studies showed
high risk of reporting bias, highlighting the aspects or
domains that were more likely to show high impact than
those that did not. This may well reflect that certain do-
mains are harder to measure, and should not undermine
the fact that some of these studies put a significant
amount of resources and effort in analysing cases, inter-
views and bibliometric databases and evidence of tri-
angulation of different methodologies [13, 16, 21].
Finally, seven out of 13 studies had a high risk of selec-
tion bias, focusing purposively on cases, which were
likely to create impact, therefore tending to overestimate
the general impact of funded research. The use of pur-
posive sampling may well be considered the best way of
providing evidence of funded research “which has gener-
ated benefits to and wider impacts on health” [21] and
the authors were very transparent in stating that in their
reports. As Morgan Jones et al. clearly put it, their
“study was commissioned as a synthesis of impacts and
benefits, not an evaluation” [21] and acknowledge this as
a limitation of their study.
Our review is not without limitations. We included in
our analysis only peer-reviewed studies to ensure that
the studies had been subject to criticism and met the
standards for scientific publication. This means that we
excluded studies that may be reporting on the impact of
funded research but were not peer reviewed. Indeed,
some funders themselves put significant effort to cele-
brate their successes, including, for instance, the Medical
Research Council’s annual impact reports [27] and the
Wellcome Trust’s system of tracking the career of its
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fellows [28]. We also acknowledge the challenge of
extracting precise information from all studies, given the
heterogeneity and nature of some of them. As an ex-
ample, the study by Morgan Jones et al. [21] included
100 case studies showing impact on different aspects of
the Payback Framework, which made the summary and
synthesis of results difficult. In addition, we chose to
look at the literature from 2006 onwards, as the launch
of the NIHR that year was seen as a significant change
in public funding of research in the United Kingdom.
This choice means that we may have missed out on im-
pact assessment studies that were conducted before
2006. Finally, we acknowledge that our choice of jour-
nals to hand-search was likely to be restricted and a
wider range of journals could have been added.
Our results could be of potential interest to public and
charity funders. The limited number of studies identified
in this review highlights the need for a more systematic
collection of data that will enable them to show that
their investment offers value for money, in particular in
areas where evidence is harder to establish such as pol-
icy development and wider societal effects. Significant
effort towards that direction has been made in the last
decade, including the introduction of Researchfish® [29],
a comprehensive digital platform to collect research out-
puts and other elements of wider impact produced by
each research project funded by a large number of
United Kingdom research organisations. These platforms
are not without caveats, as they rely on self-reporting of
outcomes, but they have certainly helped to embed the
idea that at the end of a project impact should be both
measured and reported. Other funders have developed
spreadsheets to allow researchers to report specific out-
puts arising from research projects supported by the
funder [28].
There is recognition that research activities have a de-
gree of risk and unpredictability [30] and that scientific
knowledge is often obtained in the process of trial and
error. As a result, thorough assessment of health re-
search impact can be encountered with some criticism
and interpreted as “neglecting the inherent value of sci-
ence” [31]. Nevertheless, some degree of evaluation of
funded research is needed to ensure transparency and
accountability as research funding entities are subject to
growing pressure to demonstrate the impact generated
by their funded research. Our study suggests that there
is still space for improvement.
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